Baudax Bio IncOTC Pink - Limited Information:BXRXQ
- LAST PRICE0.0100
- TODAY'S CHANGE (%)-0.0003 (-2.9126%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0105 / 0.0103
- Day Range
- 52 Week Range
- Volume88,524
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BXRXQ |
|---|---|---|
| 09:48 ET | 4632 | 0.0105 |
| 10:48 ET | 104 | 0.0107 |
| 11:15 ET | 1896 | 0.0107 |
| 11:18 ET | 25719 | 0.0104 |
| 11:20 ET | 9910 | 0.0104 |
| 11:29 ET | 25886 | 0.01 |
| 11:58 ET | 20000 | 0.01 |
| 01:26 ET | 314 | 0.01 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Baudax Bio Inc | 449.0K | 0.0x | --- |
Affymax Inc | 26.2K | 0.0x | --- |
Mymetics Corp | 1.5K | 0.0x | --- |
Kaleido Biosciences Inc | 4.3K | 0.0x | --- |
Statera Biopharma Inc | 50.0K | 0.0x | --- |
Acura Pharmaceuticals Inc | 660.0K | -0.5x | --- |
Company Information
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
Contact Information
- Headquarters
- 490 Lapp RoadMALVERN, PA, United States 19355
- Phone
- 484-395-2470
- Fax
- 484-395-2471
Executives
- Independent Chairman of the Board
- Wayne Weisman
- President, Chief Executive Officer, Director
- Geraldine Henwood
- Interim Chief Financial Officer
- Natalie Mcandrew
- Director
- Yong Chan Kim
- Independent Director
- William Ashton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $449.0K |
|---|---|
Revenue (TTM) | $310.0K |
Shares Outstanding | 43.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.53 |
EPS | $-17.25 |
Book Value | $-14.93 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,131.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
